| __timestamp | Agios Pharmaceuticals, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 9335772 |
| Thursday, January 1, 2015 | 35992000 | 12390000 |
| Friday, January 1, 2016 | 50714000 | 25602000 |
| Sunday, January 1, 2017 | 71124000 | 21262000 |
| Monday, January 1, 2018 | 114145000 | 28430000 |
| Tuesday, January 1, 2019 | 132034000 | 40849000 |
| Wednesday, January 1, 2020 | 149070000 | 60210000 |
| Friday, January 1, 2021 | 121445000 | 83664000 |
| Saturday, January 1, 2022 | 121673000 | 104097000 |
| Sunday, January 1, 2023 | 119903000 | 106916000 |
| Monday, January 1, 2024 | 156784000 |
Data in motion
In the competitive world of biotechnology, managing operational costs is crucial for success. Agios Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc. have been navigating this landscape with varying strategies since 2014. Over the past decade, Agios has consistently outpaced Iovance in Selling, General, and Administrative (SG&A) expenses, peaking in 2020 with a 680% increase from 2014. Meanwhile, Iovance has shown a remarkable growth trajectory, with its SG&A expenses surging by over 1,000% during the same period. This trend highlights the aggressive expansion and investment strategies of both companies. By 2023, the gap between the two narrowed significantly, with Agios spending only about 12% more than Iovance. This convergence suggests a shift in strategic priorities, possibly indicating Iovance's growing market presence and Agios's focus on optimizing operational efficiency.
Breaking Down SG&A Expenses: AstraZeneca PLC vs Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Agios Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Amneal Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Catalyst Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.
Iovance Biotherapeutics, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?